Home
Search
Study Topics
Glossary
|
|
|
|
|
|
Sponsored by: |
Abbott |
---|---|
Information provided by: | Abbott |
ClinicalTrials.gov Identifier: | NCT00650390 |
The study was to explore the efficacy of adalimumab in subjects previously treated with infliximab and failed infliximab treatment due to lack of efficacy or intolerance. To explore the safety of adalimumab in subjects previously treated with infliximab.
Condition | Intervention |
---|---|
Rheumatoid Arthritis |
Biological: adalimumab |
Study Type: | Expanded Access |
Official Title: | Open Label Study to Assess Efficacy and Safety of the Fully Human Anti-TNF-Alpha Monoclonal Antibody Adalimumab |
Ages Eligible for Study: | 18 Years and older |
Genders Eligible for Study: | Both |
Inclusion Criteria:
Exclusion Criteria:
Responsible Party: | Abbott ( Lawrence McNamee ) |
Study ID Numbers: | M02-532 |
Study First Received: | March 28, 2008 |
Last Updated: | March 28, 2008 |
ClinicalTrials.gov Identifier: | NCT00650390 |
Health Authority: | Germany: Ministry of Health |
Antibodies, Monoclonal Antibodies Autoimmune Diseases Musculoskeletal Diseases Joint Diseases Arthritis |
Connective Tissue Diseases Arthritis, Rheumatoid Rheumatic Diseases Adalimumab Immunoglobulins |
Anti-Inflammatory Agents Immunologic Factors Immune System Diseases Therapeutic Uses |
Physiological Effects of Drugs Antirheumatic Agents Pharmacologic Actions |